| Document |
Document Title |
|
WO/2023/163140A1 |
The purpose of the present invention is to provide a compound that exhibits an H-PGDS inhibitory activity. The present invention relates to a compound expressed by formula [I] or a pharmaceutically acceptable salt thereof (in the formula...
|
|
WO/2023/163170A1 |
The embolic agent according to the present invention is a copolymer formed from a cationic functional group-containing monomer and an aromatic group-containing monomer, said embolic agent having, as an active ingredient, a copolymer whic...
|
|
WO/2023/161505A1 |
The present invention relates to compounds of formula (I), which are modulators of sortilin activity, pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditi...
|
|
WO/2023/160700A1 |
Provided herein are compositions and methods for treating cardiovasculardisease, particularly those known to be caused by endothelial dysfunctions due to nitricoxide (NO) deficiency in patients.The colloidal coordination compounds, inclu...
|
|
WO/2023/164431A1 |
Embodiments of the present disclosure relate to the use of bupivacaine multivesicular liposomes (MVLs) as stellate ganglion block (SGB) for treating or ameliorating various diseases and conditions, including but not limited to cardiac el...
|
|
WO/2023/159601A1 |
USE of an agent that deacetylates a transcription factor KLF4 to promote a transcriptional activity thereof in preparation of a medicament for treating pulmonary arterial hypertension is provided. The agent is configured to deacetylate t...
|
|
WO/2023/161227A1 |
The present invention relates to a complex coacervate comprising lactoferrin and osteopontin, processes of producing the same and composition comprising the same. Moreover, the present invention relates to complexes comprising lactoferri...
|
|
WO/2023/163521A1 |
The present invention relates to a DNA aptamer specifically binding to LDL, and a use of the DNA aptamer. Specifically, the DNA aptamer, according to the present invention, specifically binds to LDL with high affinity and inhibits LDL wh...
|
|
WO/2023/160344A1 |
Disclosed are a NO donor compound, a preparation method therefor, a pharmaceutical composition comprising same, and use thereof. The structure of the compound is represented by formula I. The NO donor compound and the pharmaceutical comp...
|
|
WO/2023/163596A1 |
The invention relates to certain chromanol, quinone or hydroquinone compounds and derivatives thereof for treatment or prophylaxis of aging, or idiopathic ageing-associated disorders such as vascular ageing or reduced renal function. Spe...
|
|
WO/2023/164440A1 |
Provided herein are cell and protein therapeutics that comprise a Proteinase 3 (PR3) antibody binding domain, such as a wild type PR3 protein or mutant PR3 protein, and methods of use thereof. Also provided herein are chimeric autoantibo...
|
|
WO/2023/158159A1 |
The present invention relates to a nanodisc comprising angiotensin converting enzyme 2 (ACE2) and a membrane scaffold protein (MSP). In the present invention, the angiotensin converting enzyme 2 (ACE2) is included in the nanodisc, and it...
|
|
WO/2023/158634A1 |
Described herein are crystalline forms of a prostacyclin (IP) receptor agonist compound, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatm...
|
|
WO/2023/156768A1 |
The present disclosure provides compositions which may be useful in the generation of vitamin D and/or nitric oxide, in particular when exposed to radiation (e.g. light and/or UV radiation). The disclosure further provides methods of gen...
|
|
WO/2023/155873A1 |
The present application provides a carboxylic acid compound, a method for preparing same, and use thereof in pharmaceutics. Specifically, the present application provides a carboxylic acid compound represented by formula (I), a method fo...
|
|
WO/2023/155900A1 |
Provided in the present invention are a preparation and use of a five-membered and six-membered heterocyclic compound, and particularly provided is a compound as shown in the following formula I, wherein the definition of each group is a...
|
|
WO/2023/155756A1 |
Disclosed in the present invention is the use of a lipoic acid nanoparticle in the preparation of a drug for treating diseases related to oxidative stress, which belongs to the technical field of biomedicine. The drug for treating diseas...
|
|
WO/2023/158681A1 |
Methods, uses, and kits are provided for treating a subject having impaired perfusion by administering an extended delivery regimen of a blood cell growth factor to stimulate fibrinolysis and/or neovascularization. The methods, uses, and...
|
|
WO/2023/156911A1 |
The present disclosure provides pharmaceutical compositions comprising thiotepa, water, one selected from PEG, such as PEG400 or PEG600, and DMSO, and optionally thiosulfate or such compositions which is free or substantially free of imp...
|
|
WO/2023/159150A1 |
Disclosed herein include methods for preventing, inhibiting, reducing, or treating cardiac ischemic injury. The method comprises administering a therapeutic composition comprising a plurality of microRNA (miR) antagonists to a subject be...
|
|
WO/2023/152500A1 |
The present disclosure relates to the technical field of medicaments. Particularly, the present disclosure provides a pharmaceutical combination/composition comprising a phosphodiesterase type 5 (PD1 5) inhibitor, arginine, and N-acetyle...
|
|
WO/2023/154705A1 |
The disclosure relates to treatment of a disease, such as pulmonary hypertension, by inhalation with a combination of iloprost and treprostinil.
|
|
WO/2023/154850A2 |
Fragile X Mental Retardation protein (FMRP) is an RNA-binding protein (RBP) that controls translation of select mRNAs. We discovered that endoplasmic reticulum (ER) stress induces phosphorylation of FMRP on a site that is known to enhanc...
|
|
WO/2023/153902A1 |
The present invention relates to a composition for inhibiting preadipocyte differentiation and lipid accumulation, comprising Enterococcus faecalis as an active ingredient. Particularly, it was confirmed that killed E. faecalis EF-2001 i...
|
|
WO/2023/154014A1 |
The usage of NMDAR antagonists provides compositions and methods for treatment for the malfunctioning of the protein homeostasis network and interferes with crucial signaling pathways and is often associated with multiple human diseases....
|
|
WO/2023/154499A1 |
Provided are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.
|
|
WO/2023/152698A1 |
The present invention relates to compounds of formula (I): as activators of glucagon-like peptide 1 (GLP1) receptor for the treatment of obesity, type 2 diabetes mellitus, insulin resistance, hyperinsulinemia, glucose intolerance, hyperg...
|
|
WO/2023/154479A1 |
The present disclosure relates to a formulations and methods for transdermal delivery of a medicament through the skin of a subject. In aspects, the formulation comprises a therapeutically effective amount of a medicament and a penetrant...
|
|
WO/2023/154933A1 |
Treatments and methods for inhibiting late Na current use fibroblast growth factor homologous factor (FHF), an endogenous channel modulator, to inhibit late Na current with high potency. A minimal effector domain is engineered within FHF...
|
|
WO/2023/154923A2 |
The present disclosure generally provides compositions and methods for increasing the activity of an annexin protein to treat a cellular membrane injury in a patient in need thereof. In some aspects, the disclosure provides methods of tr...
|
|
WO/2023/152761A1 |
The present invention relates to crystalline rosuvastatin allyl ester (1), to a process for its manufacture, to pharmaceutical compositions comprising it as well as the use of crystalline (1 ) in medicine. The medicine can be useful, for...
|
|
WO/2022/174116A9 |
The disclosure relates to methods of producing nitric oxide (NO) gas that is administrable without specialized equipment and does not provide nitrogen dioxide (NO2) gas. The methods comprise combining a nitrate and/or nitrite anion and a...
|
|
WO/2023/150258A1 |
The invention relates to methods for treating atrial fibrillation or for preventing or reversing atrial remodeling comprising administering retinoids, such as, for example, all-trans retinoic acid (ATRA).
|
|
WO/2023/148501A1 |
The present invention relates to compounds of formula (I) that are MALT1 inhibitors. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to p...
|
|
WO/2023/148203A1 |
The invention relates to a pharmaceutical composition comprising a soluble guanylate cyclase stimulator or salt thereof for use in the treatment of a medical condition comprising a chronic vascular dysfunction occurring or persisting aft...
|
|
WO/2023/149701A1 |
The present invention provides a pharmaceutical composition comprising a therapeutically effective amount of allopurinol, febuxostat, or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating cardio...
|
|
WO/2023/150374A1 |
The present disclosure provides compounds that are inducers of KLF2 and pharmaceutical compositions comprising the same. The present disclosure further provides method of treating an inflammatory disease or endothelial dysfunction compri...
|
|
WO/2023/147868A1 |
Provided herein are methods for treating pulmonary hypertension. The methods include formulation of stable and highly concentrated imatinib solutions, selection of inhalers and nebulizers capable of aerosolizing such stable and highly co...
|
|
WO/2023/145959A1 |
A medicine for treating or preventing interstitial lung disease and the disease or symptoms associated with systemic scleroderma in a subject, said medicine containing, as an active ingredient, 1-\{2-[(3S,4R)-1-\{[(3R,4R)-1-cyclopentyl-3...
|
|
WO/2023/142889A1 |
The present invention relates to a use of kallikrein I or a derivative thereof in the treatment of vascular cognitive impairment (VCI), post-stroke cognitive impairment (PSCI) or cerebral small vessel disease (CSVD).
|
|
WO/2023/143293A1 |
A pharmaceutically acceptable salt type and crystal form of a compound as represented by the following formula (I), and a preparation method of the compound and an application thereof.
|
|
WO/2023/144736A1 |
The present invention relates to a pharmaceutical composition for preventing or treating pulmonary arterial hypertension, comprising a compound represented by formula I, optical isomers thereof or pharmaceutically acceptable salts thereo...
|
|
WO/2023/146785A1 |
The present disclosure provides compounds of the formula (III) and their pharmaceutically acceptable salts, and compounds of the formula (IV) and their pharmaceutically acceptable salts, and pharmaceutical compositions comprising these c...
|
|
WO/2023/143402A1 |
Disclosed in the present invention are a steroid compound, a preparation method therefor, and an application thereof. The steroid compound can have a structure shown in formula I. The compound of the present invention has SREBP pathway i...
|
|
WO/2023/143482A1 |
The present invention relates to a 2-aminopyrimidine compound as shown in formula (I), a pharmaceutically acceptable salt, a tautomer, a stereoisomer, a solvate or a prodrug thereof, a preparation method therefor, and a pharmaceutical co...
|
|
WO/2023/145735A1 |
Provided is a new therapy/prevention for aging-related disorders including sarcopenia. The present invention pertains to a pharmaceutical composition that contains an expectorant (examples thereof include compounds, or pharmaceutically a...
|
|
WO/2023/143205A1 |
Disclosed in the present invention are a crystal form of a class of 7-azaspiro[4,5]decane-6,10-dione compounds and a preparation method therefor. Specifically disclosed are a method for preparing a compound of formula (I) and a crystal f...
|
|
WO/2023/141724A1 |
There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosu...
|
|
WO/2023/143401A1 |
The present invention relates to a compound having inhibitory activity for the lectin pathway of complement, a preparation method therefor, and an application thereof. Specifically, the present invention relates to a compound as represen...
|
|
WO/2023/144596A1 |
A method for treating at least one heart disease caused by a liver failure comprises administrating a low dosage of a composition of biguanide component along with a low amount of cyclosporine component to a subject in need thereof for a...
|
